DYN Dyne Therapeutics, Inc.
Executive Summary
During Q3 2024, DYN saw a mixed institutional cluster: 10 buyers (accumulating $136.9M) faced off against 7 sellers (reducing $100.5M), with active managers like Janus Henderson, Avoro Capital, and Farallon adding large positions while quant funds Citadel and Point72 trimmed significantly. The net $36.4M inflow suggests cautious optimism, but the 45-day 13F reporting lag and divergent quant selling temper conviction.
Key Financial Metrics
Institutional Positions
Net institutional flow: $36.4M
▲ Buyers (10)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Janus Henderson Group | ADD | +47.3% | $244.8M | $81.5M |
| Avoro Capital Advisors | DOUBLED | +461.6% | $23.3M | $19.3M |
| Farallon Capital Management | DOUBLED | +7033.3% | $15.4M | $15.2M |
| Norges Bank | DOUBLED | +303.7% | $15.5M | $11.8M |
| Ameriprise Financial | DOUBLED | +718% | $7.6M | $6.7M |
▼ Sellers (7)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citadel | TRIM | -31.9% | $152.3M | -$46.7M |
| Adage Capital Partners GP | TRIM | -27.8% | $117.4M | -$31.1M |
| Point72 | TRIM | -71.3% | $12.6M | -$8.9M |
| Invesco | NEAR_EXIT | -83.7% | $9.2M | -$7.6M |
Actionable Insight
The cluster shows active-manager conviction (Janus, Avoro, Farallon) outweighing quant selling, but the 45-day lag means current positioning may differ. Watch for next earnings/catalyst update (pipeline data readouts) and any further insider buying to confirm the bullish thesis. The mixed signal suggests a wait-and-see approach rather than immediate directional bet.
Key Facts
- 10 institutional buyers added $136.9M in new positions; 7 sellers reduced by $100.5M (net +$36.4M)
- Janus Henderson Group added $81.5M (current $244.8M); Avoro Capital added $19.3M; Farallon added $15.2M
- Citadel trimmed $46.7M (current $105.6M); Adage Capital trimmed $31.1M; Point72 trimmed $8.9M
- Invesco near-exited (-83.7% of shares), indicating passive rebalancing or risk reduction
- 85% analyst bullish consensus; 4 insider buys totaling $157K in the last 30 days
- 13F data is as of Q3 2024 end; positions may have changed since the filing date
Financial Impact
Net institutional accumulation of $36.4M: $136.9M in buying vs $100.5M in selling during Q3 2024
Risk Factors
- 45-day 13F disclosure lag; positions may have been unwound or adjusted since quarter-end
- Significant quant selling (Citadel, Point72) suggests professional short-term bearish thesis or risk management
- Dyne Therapeutics is a pre-revenue biotech with binary pipeline risk; clinical trial results could reverse the accumulation thesis
Market Snapshot
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-DYN-2024-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
Institutional Cluster
| $17.96 awaiting T+1 | awaiting T+1 | — | — |
|
Jun 3, 2026
10d ago
|
8-K
| $17.99 $18.41 | ▲ +2.33% | ▲ +1.94% | — |
|
Jun 3, 2026
10d ago
|
Press Release
| $17.99 $18.41 | ▲ +2.33% | ▲ +1.94% | — |
|
May 20, 2026
23d ago
|
Press Release
| $17.37 $17.37 | · 0.00% | ▼ −0.45% | — |
|
May 20, 2026
24d ago
|
Press Release
| $17.56 $17.37 | ▼ −1.08% | ▼ −1.28% | — |
|
May 13, 2026
4w ago
|
144
| $18.28 $17.29 | ▼ −5.42% | ▼ −4.19% | — |
|
May 13, 2026
4w ago
|
144
| $18.28 $17.29 | ▼ −5.42% | ▼ −4.19% | — |
|
May 11, 2026
4w ago
|
8-K
| $18.46 $18.37 | ▼ −0.49% | ▼ −0.35% | — |
|
May 6, 2026
5w ago
|
144
| $17.54 $17.61 | ▲ +0.40% | ▼ −0.43% | — |
|
May 6, 2026
5w ago
|
144
| $17.54 $17.61 | ▲ +0.40% | ▼ −0.43% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access